Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 3:21 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 1,099 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Healthy Control Subjects Clear all

Conditions: Rabies
Interventions: CL184, HRIG, Placebo matching CL184; Biological
Lead sponsor: Crucell Holland BV; Industry
Eligibility: 19 Years to 65 Years
Enrollment: 140 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Infections, Bacterial
Interventions: Gepotidacin RC Tablet, Gepotidacin HSWG Tablet, Gepotidacin Capsule; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 2
States / cities: Anaheim, California • Austin, Texas

Conditions: Healthy
Interventions: PF-03463275, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Glendale, California

Conditions: Migraine
Interventions: PF-05180999, Placebo, 120 mg MR PF-05180999, 360 mg MR PF-05180999, 10 mg cetirizine; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 31 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Saint Paul, Minnesota

Conditions: Immunoglobulin A Nephropathy, IgAN - IgA Nephropathy, IgA Nephropathy
Interventions: VIS649, Placebo; Biological
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 51 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Glendale, California

Conditions: Depression, Involutional, Healthy
Interventions: Not listed
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: 18 Years to 60 Years
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2005
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Herpes Zoster, Varicella Zoster
Interventions: CRV 101, Placebo; Biological
Lead sponsor: Curevo Inc; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 90 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Kansas City, Missouri

Conditions: Long QT Syndrome
Interventions: GS-6615, Placebo to match GS-6615, Placebo to match dofetilide, Dofetilide; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 40 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: West Bend, Wisconsin

Conditions: Healthy Volunteers
Interventions: VEL-101, Placebo; Drug
Lead sponsor: Veloxis Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Hypertension, Mineralocorticoid Receptor Antagonist
Interventions: CS-3150, Moxifloxacin, Placebo matching moxifloxacin tablet, Placebo matching CS-3150; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 55 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Healthy Volunteer Study
Interventions: CBP-4888, Placebo; Drug · Other
Lead sponsor: Comanche Biopharma; Industry
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Analgesia
Interventions: KP-1199, Placebo oral capsule, Oxycodone oral capsule; Drug
Lead sponsor: Kalyra Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Tuberculosis, Tuberculosis, Pulmonary
Interventions: Sutezolid, Placebo; Drug
Lead sponsor: Global Alliance for TB Drug Development; Other
Eligibility: 19 Years to 50 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Healthy Volunteers
Interventions: KINE-101, Placebo; Drug
Lead sponsor: Kine Sciences Co., Ltd.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Healthy
Interventions: Clopidogrel, Placebo, Pantoprazole; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 66 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Nipah Virus Infection
Interventions: PHV02, Lactated Ringer's; Biological
Lead sponsor: Public Health Vaccines LLC; Industry
Eligibility: 18 Years to 59 Years
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 3
States / cities: Anaheim, California • Hollywood, Florida • Salt Lake City, Utah

Conditions: Abdominal Discomfort, Bloating
Interventions: B. infantis 35624, placebo; Dietary Supplement
Lead sponsor: Procter and Gamble; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 302 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 10
States / cities: Chicago, Illinois • Rockford, Illinois • Indianapolis, Indiana + 7 more

Conditions: Dyslipidemia
Interventions: AZD0780, Placebo, Rosuvastatin; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 183 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 2
States / cities: Glendale, California • Brooklyn, Maryland

Conditions: Obesity
Interventions: HM15275, Placebo of HM15275; Drug
Lead sponsor: Hanmi Pharmaceutical Company Limited; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 74 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Chula Vista, California

Conditions: Healthy
Interventions: Diacerein 1% ointment; Drug
Lead sponsor: Castle Creek Pharmaceuticals, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Fair Lawn, New Jersey

Conditions: Tolerability, Healthy, Elderly
Interventions: AZD9742, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 65 Years and older
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Springfield, Missouri

Conditions: Atopic Dermatitis (AD), Eczema
Interventions: ARQ-234, Placebo; Biological · Drug
Lead sponsor: Arcutis Biotherapeutics, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 125 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 7
States / cities: Miami, Florida • Plainfield, Indiana • Fair Lawn, New Jersey + 3 more

Conditions: Pneumococcal Vaccines
Interventions: 31-valent pneumococcal conjugate vaccine, PCV20; Biological
Lead sponsor: Vaxcyte, Inc.; Industry
Eligibility: 50 Years and older
Enrollment: 752 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 30
States / cities: Chinle, Arizona • Phoenix, Arizona • Whiteriver, Arizona + 27 more

Conditions: Healthy
Interventions: STSA-1002 injection, Placebo; Drug
Lead sponsor: Staidson (Beijing) Biopharmaceuticals Co., Ltd; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Overland Park, Kansas

Search by objective public record fields.

A Randomized Phase II Trial to Compare the Safety and Neutralizing Activity of CL184 in Combination With Rabies Vaccine vs. HRIG or Placebo in Combination With Rabies Vaccine in Healthy Adult Subjects

To Assess Bioavailability, Food Effect and Pharmacokinetics of Gepotidacin Tablets: A Phase I, Single-Dose, 2 Part Study in Healthy Subjects.

Pharmacokinetics, Safety and Tolerability Study of PF-03463275 in Healthy Male Japanese and Western Subjects

A Study of the Safety, Tolerability, Pharmacokinetics, And Effects On Histamine-Induced Wheal Of PF-05180999 In Healthy Adults

First in Human Study to Assess Safety of VIS649 in Healthy Subjects

Serotonin Function During Depression

Safety, Tolerability, and Immunogenicity of CRV-101 in Healthy Adult Subjects

Effect of Oral GS-6615 on Dofetilide-Induced QT Prolongation, Safety, and Tolerability in Healthy Adults

A Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VEL-101

The Effect of CS-3150 Exposure on Corrected QT (QTc) Interval Duration in Healthy Volunteers

Study of CBP-4888 in Healthy, Non-Pregnant Female Subjects

A Single and Multiple Ascending Dose Study in Healthy Subjects to Assess the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of KP-1199

Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Sutezolid

A First-in-Human Study of KINE-101 in Healthy Volunteers

Interaction Study of Clopidogrel 300/75 mg Given Alone or Concomitantly With Pantoprazole 80 mg in Healthy Subjects

Study to Evaluate Safety and Immunogenicity of a Prime-Boost Regimen of rVSV-Nipah Virus Vaccine Candidate PHV02 in Healthy Adult Subjects

Study to Evaluate a Probiotic in Healthy Subjects With a History of Abdominal Discomfort and Bloating

A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD0780 in Healthy Subjects

A Phase 1 Study to Assess HM15275 in Healthy and Obese Subjects.

A 4-Day Study to Evaluate the Photoxicity of Diacerein 1% Topical Ointment in Healthy Volunteers

Assessing the Safety and Tolerability of a Single IV Dose of AZD9742 in Healthy Elderly Male and Female Subjects

Ph 1a/1b Single Ascending Dose and Multiple Ascending Dose Study of ARQ-234

Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Prior Pneumococcal Vaccination

The Safety and Tolerability of STSA-1002 Following Intravenous Infusion in Healthy Subjects